NCT05947344View on ClinicalTrials.gov

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

PHASE1RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
AML, Adult
Interventions
DRUG

STI-8591

Four dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg, 60mg and 80mg. Expansion is planned in two dose groups of 40mg and 60mg.

Trial Locations (1)

Unknown

RECRUITING

the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang ACEA Pharmaceutical Co. Ltd.

INDUSTRY